medi-cal no longer covering glp-1 coverage of weight loss drugs on chopping block under CA proposal Big News: Medicare & Medicaid

Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study

In previously healthy individuals over 50 who experience the sudden onset of diabetes, and in those patients with newly diagnosed chronic pancreatitis who also present with weight loss, glycemic decompensation, abdominal pain, and other abdominal symptoms, a one-time assessment using high-resolution pancreatic imaging (MRCP or EUS) is warranted to rule out the possibility of occult PDAC

however, the clinical significance of these findings remains uncertain [18]

Pair fats with protein instead of sugar, and your metabolism will thank you

The FDA Adverse Event Reporting System now shows a reporting odds ratio of 2.46 for alopecia with semaglutide, meaning hair loss reports are nearly two and a half times higher than expected

These drugs that are FDA-approved for the treatment of diabetes have emerged as a promising new tool in the fight against obesity